Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.

Haanen, J.; Obeid, M.; Spain, L.; Carbonnel, F.; Wang, Y.; Robert, C.; Lyon, A.R.; Wick, W.; Kostine, M.; Peters, S.; Jordan, K.; Larkin, J.

doi:10.1016/j.annonc.2022.10.001

Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.

Détails

Demande d'une copie

ID Serval

serval:BIB_F3804F73BCD6

Type

Article: article d'un périodique ou d'un magazine.

Sous-type

Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.

Collection

Publications

Institution

UNIL/CHUV

Titre

Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.

Périodique

Annals of oncology

Auteur⸱e⸱s

Haanen J., Obeid M., Spain L., Carbonnel F., Wang Y., Robert C., Lyon A.R., Wick W., Kostine M., Peters S., Jordan K., Larkin J.

Collaborateur⸱rice⸱s

ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org

ISSN

1569-8041 (Electronic)

ISSN-L

0923-7534

Statut éditorial

Publié

Date de publication

12/2022

Peer-reviewed

Oui

Volume

33

Numéro

12

Pages

1217-1238

Langue

anglais

Notes

Publication types: Practice Guideline ; Research Support, Non-U.S. Gov't ; Journal Article
Publication Status: ppublish

Mots-clé

Humans, Follow-Up Studies, Immunotherapy/adverse effects, Immunologic Factors, ESMO Clinical Practice Guideline, immunotherapy, side-effects, toxicity, treatment

OAI-PMH

oai:serval.unil.ch:BIB_F3804F73BCD6

DOI

10.1016/j.annonc.2022.10.001

Pubmed

36270461

Web of science

000898986900004

Open Access

Oui

Création de la notice

10/09/2017 15:28